logo

For the Inventor, By the Inventor

Rome, Italy

Domenico Misiti

USPTO Granted Patents = 19

Average Co-Inventor Count = 3.8

ph-index = 4

Forward Citations = 48(Granted Patents)


Company Filing History:

goldMedal18 out of 343 
 
Sigma-Tau Industrie Farmaceutiche Riunite S.p.a.
 patents
silverMedal1 out of 1 
 
501 Sigma Tau Industrie Farmaceutiche Riunite S.p.a.
 patent

Years Active: 1989-1996

Loading Chart...
19 patents (USPTO):Explore Patents
1. 5547986 - Ester of L-carnitine with gamma-hydroxybutyric acid and pharmaceutical (1996-08-20),
2. 5543556 - Esters of acyl l-carnitines with gamma-hydroxybutyric acid and (1996-08-06),
3. 5534549 - Easters of acyl L-carnitines with gamma-hydroxybutyric acid and (1996-07-09),
4. 5532409 - Process for producing R-aminocarnitine and S-aminocarnitine (1996-07-02),
5. 5525627 - Esters of acyl carnitines with long-chain aliphatic alcohols and (1996-06-11),
6. 5519056 - Esters of acyl carnitines with long-chain aliphatic alcohols and (1996-05-21),
7. 5498633 - Esters of acyl carnitines with long-chain aliphatic alcohols and (1996-03-12),
8. 5498632 - Esters of acyl carnitines with long-chain aliphatic alcohols and (1996-03-12),
9. 5491260 - Process for manufacturing L-(-)-carnitine from derivatives having a (1996-02-13),
10. 5227496 - Pyroglutamic acid derivatives as enhancers of learning processes and (1993-07-13),
11. 5192759 - Derivatives of 1,2,3,4-tetrahydronaphtylamine endowed with nootropic (1993-03-09),
12. 5166150 - Pharmaceutical compositions comprising 3-amino-.epsilon.-caprolactames (1992-11-24),
13. 5102896 - 1-acyl-2-pyrrolidinones as enhancers of learning and memory (1992-04-07),
14. 5061725 - (Pyrrolidin-2-one-1-yl) acetamides and enhancers of learning and memory (1991-10-29),
15. 5047433 - N-alkyl derivatives of 2-amino-6,7-dimethoxy tetraline and (1991-09-10),

Title: **The Innovations of Inventor Domenico Misiti**

Introduction

Domenico Misiti, a distinguished inventor based in Rome, Italy, has made significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 19 patents, Misiti is known for his innovative formulations that aim to address critical health issues, particularly neurodegenerative diseases.

Latest Patents

Among his recent inventions is the patent for the ester of L-carnitine with gamma-hydroxybutyric acid, which is designed to produce pharmacologically acceptable salts. This invention has shown potential in inhibiting neuronal degeneration associated with conditions such as Alzheimer's disease and Parkinson's disease, as well as aiding in the treatment of coma. Another notable patent involves esters of acyl L-carnitines with gamma-hydroxybutyric acid, where the esters are also formulated as pharmacologically acceptable salts. These compounds have similar therapeutic applications aimed at treating debilitating neurological conditions.

Career Highlights

Domenico Misiti has had an impactful career, working with Sigma-Tau Industrie Farmaceutiche Riunite S.p.a., a notable pharmaceutical company where he enhanced his expertise in drug formulation and development. His active role in this company reflects his commitment to creating innovative solutions for health care challenges.

Collaborations

Misiti's journey has been marked by fruitful collaborations with esteemed colleagues, including Maria Ornella Tinti and Fabio Giannessi. Together, they have contributed to advancing pharmaceutical science, emphasizing the importance of teamwork in achieving groundbreaking scientific innovations.

Conclusion

Domenico Misiti's advancements in the pharmaceutical industry have showcased his ingenuity and dedication to innovation. His patents hold the promise of offering new therapeutic avenues for the treatment of neurodegenerative diseases, reflecting the critical role inventors play in improving health outcomes worldwide. As he continues to work and innovate, the impact of his discoveries will undoubtedly resonate within the medical and scientific communities.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…